Welcome!

News Feed Item

Healthcare Companies Report Transactions, Appeals, New Research Findings and Stock Movements - Analyst Notes on Johnson & Johnson, Teva, Celgene, Cara Therapeutics, and OncoMed Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 3, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Celgene Corporation (NASDAQ: CELG), Cara Therapeutics Inc. (NASDAQ: CARA), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Johnson & Johnson Analyst Notes 

On March 31, 2014, Johnson & Johnson announced that it has accepted the binding offer from The Carlyle Group. According to the release, the binding offer was received and announced on January 16, 2014, to acquire the Company's Ortho-Clinical Diagnostics business for approximately $4 billion, subject to customary adjustments. Additionally, the Company stated that the acceptance was made after consultation with the relevant works councils and trade unions. Johnson & Johnson also stated that the transaction is expected to close towards the middle of the year, upon satisfaction of customary closing conditions and that it will discuss any updates on the transaction during its scheduled quarterly earnings call on April 15, 2014. The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.AnalystsReview.com/04032014/JNJ/report.pdf

--

Teva Pharmaceutical Industries Limited Analyst Notes 

On March 31, 2014, Teva Pharmaceutical Industries Limited (Teva) announced that its COPAXONE® certiorari petition has been granted by the U.S. Supreme Court and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (808 patent). According to the release, the 808 patent expires on September 1, 2015, and claims a process for manufacturing the active ingredient of the Company's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE® (glatiramer acetate injection) 20mg/L. Additionally, the Company stated that it has previously prevailed in the District Court regarding nine COPAXONE® patents, including the 808 patent. Teva also stated that any purported generic version of COPAXONE® would be required to obtain the Food and Drug Administration's (FDA) approval prior to being made available to the public. The full analyst notes on Teva Pharmaceutical Industries Limited are available to download free of charge at:

http://www.AnalystsReview.com/04032014/TEVA/report.pdf

--

Celgene Corporation Analyst Notes 

On March 23, 2014, Celgene Corporation (Celgene) announced that it has released new research findings on OTEZLA® (apremilast) from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) in Denver, CO. According to Celgene, in ESTEEM 1 and 2, patients were given OTEZLA 30mg twice daily (BID) or placebo for the first 16 weeks, then followed by a maintenance phase through week 32, in which patients on placebo for 16 weeks were switched to OTEZLA. Additionally, the Company stated that patients initially randomized to OTEZLA 30 mg BID, and those who were PASI 75 (Psoriasis Area and Severity Index) responders at week 32, were re-randomized to either OTEZLA 30mg BID or placebo. Commenting on the news, Jennifer Cather, M.D., Modern Research Associates, Dallas Texas, stated, "Results from the 52-week analysis of the ESTEEM program suggest that early responses seen with OTEZLA treatment in multiple efficacy endpoints of plaque psoriasis, including difficult to treat areas, are durable over time. Together with the observed long-term consistent safety and tolerability profile, these findings are encouraging." The full analyst notes on Celgene Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04032014/CELG/report.pdf

--

Cara Therapeutics Inc. Analyst Notes 

On March 31, 2014, Cara Therapeutics Inc.'s (Cara Therapeutics) stock went up by 12.65%, at $18.61 per share. For the past three-month trading period, Cara Therapeutics' shares reflected an increase of 44.14%, compared to the Nasdaq Composite which went up by 2.31% over the same three-month trading period. The full analyst notes on Cara Therapeutics Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/CARA/report.pdf

--

OncoMed Pharmaceuticals, Inc. Analyst Notes 

On March 31, 2014, OncoMed Pharmaceuticals, Inc.'s (OncoMed Pharmaceuticals) stock went up by 15.87%, at $33.65 per share. Over the past six-month trading period, the Company's stock increased significantly by 119.79%, compared to the Nasdaq Composite which went up by 11.33% during the same trading session. The full analyst notes on OncoMed Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/OMED/report.pdf

--


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that CrowdReviews.com has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5–7, 2018, at the Javits Center in New York City, NY. CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users that have experienced products and services first-hand and have an interest in letting other potential buye...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...